BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K. Relationship Among α-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra. J Neuropathol Exp Neurol 2006;65:808-15. [DOI: 10.1097/01.jnen.0000230520.47768.1a] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Abaquita TAL, Damulewicz M, Tylko G, Pyza E. The dual role of heme oxygenase in regulating apoptosis in the nervous system of Drosophila melanogaster. Front Physiol 2023;14:1060175. [PMID: 36860519 DOI: 10.3389/fphys.2023.1060175] [Reference Citation Analysis]
2 Chiu PY, Yang FC, Chiu MJ, Lin WC, Lu CH, Yang SY. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. Sci Rep 2022;12:17919. [PMID: 36289355 DOI: 10.1038/s41598-022-22647-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yoshida M, Akagi A, Miyahara H, Riku Y, Ando T, Ikeda T, Yabata H, Moriyoshi H, Koizumi R, Iwasaki Y. Macroscopic diagnostic clue for parkinsonism. Neuropathology 2022. [PMID: 35996308 DOI: 10.1111/neup.12853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Duperrier S, Bortolozzi A, Sgambato V. Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson’s Disease. IJMS 2022;23:8586. [DOI: 10.3390/ijms23158586] [Reference Citation Analysis]
5 Rozova K, Gasyuk T, Karasevich N, Karaban I. Structural damage of myelin in experimental Parkinsonism and prospects for their drug correction in the clinic of Parkinson's disease. A&L 2022. [DOI: 10.47855/jal9020-2022-2-3] [Reference Citation Analysis]
6 Boshkovski T, Cohen-Adad J, Misic B, Arnulf I, Corvol JC, Vidailhet M, Lehéricy S, Stikov N, Mancini M. The Myelin-Weighted Connectome in Parkinson's Disease. Mov Disord 2021. [PMID: 34936123 DOI: 10.1002/mds.28891] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bassil F, Delamarre A, Canron MH, Dutheil N, Vital A, Négrier-Leibreich ML, Bezard E, Fernagut PO, Meissner WG. Impaired brain insulin signalling in Parkinson's disease. Neuropathol Appl Neurobiol 2021. [PMID: 34405431 DOI: 10.1111/nan.12760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
8 Brown JM, Baker LS, Seroogy KB, Genter MB. Intranasal Carnosine Mitigates α-Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease. ACS Chem Neurosci 2021;12:2347-59. [PMID: 34138535 DOI: 10.1021/acschemneuro.1c00096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
9 Chen YH, Wu KJ, Hsieh W, Harvey BK, Hoffer BJ, Wang Y, Yu SJ. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein. Genes (Basel) 2021;12:948. [PMID: 34205689 DOI: 10.3390/genes12060948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huynh B, Fu Y, Kirik D, Shine JM, Halliday GM. Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Mov Disord 2021. [PMID: 33899954 DOI: 10.1002/mds.28615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Hansen AK, Parbo P, Ismail R, Østergaard K, Brooks DJ, Borghammer P. Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study. J Parkinsons Dis 2020;10:161-71. [PMID: 31815700 DOI: 10.3233/JPD-191774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
12 Seike N, Yokoseki A, Takeuchi R, Saito K, Miyahara H, Miyashita A, Ikeda T, Aida I, Nakajima T, Kanazawa M, Wakabayashi M, Toyoshima Y, Takahashi H, Matsumoto R, Toda T, Onodera O, Ishikawa A, Ikeuchi T, Kakita A. Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations. Mov Disord 2021;36:1634-43. [PMID: 33570211 DOI: 10.1002/mds.28521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Stevenson TJ, Murray HC, Turner C, Faull RLM, Dieriks BV, Curtis MA. α-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory nucleus of the Parkinson's disease olfactory bulb. Sci Rep 2020;10:6682. [PMID: 32317654 DOI: 10.1038/s41598-020-63412-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
14 Amano R, Toru S, Yamane M, Kitagawa M, Hirokawa K, Uchihara T. Parallel enlargement of Marinesco bodies and nuclei and progressive deposition of p62 in pigmented neurons of the substantia nigra. Neuropathology 2020;40:328-35. [PMID: 32202001 DOI: 10.1111/neup.12647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Singh S. Noradrenergic pathways of locus coeruleus in Parkinson's and Alzheimer's pathology. Int J Neurosci 2020;130:251-61. [PMID: 31575316 DOI: 10.1080/00207454.2019.1667799] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Kon T, Tomiyama M, Wakabayashi K. Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. Neuropathology 2020;40:30-9. [PMID: 31498507 DOI: 10.1111/neup.12597] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
17 Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna) 2019;126:933-95. [PMID: 31214855 DOI: 10.1007/s00702-019-02028-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
18 Wu ZC, Gao JH, Du TF, Tang DH, Chen NH, Yuan YH, Ma KL. Alpha-synuclein is highly prone to distribution in the hippocampus and midbrain in tree shrews, and its fibrils seed Lewy body-like pathology in primary neurons. Exp Gerontol 2019;116:37-45. [PMID: 30553024 DOI: 10.1016/j.exger.2018.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jellinger KA. Is Braak staging valid for all types of Parkinson's disease? J Neural Transm (Vienna) 2019;126:423-31. [PMID: 29943229 DOI: 10.1007/s00702-018-1898-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
20 Johnson M, Salvatore M, Maiolo S, Bobrovskaya L. Tyrosine hydroxylase as a sentinel for central and peripheral tissue responses in Parkinson’s progression: Evidence from clinical studies and neurotoxin models. Progress in Neurobiology 2018;165-167:1-25. [DOI: 10.1016/j.pneurobio.2018.01.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
21 Ekmark-Lewén S, Lindström V, Gumucio A, Ihse E, Behere A, Kahle PJ, Nordström E, Eriksson M, Erlandsson A, Bergström J, Ingelsson M. Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice. Brain Behav 2018;8:e00915. [PMID: 29541535 DOI: 10.1002/brb3.915] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
22 Suárez I, Bodega G, Rubio M, Fernández B. Reduced TH expression and α-synuclein accumulation contribute towards nigrostriatal dysfunction in experimental hepatic encephalopathy. Restor Neurol Neurosci 2017;35:469-81. [PMID: 28984618 DOI: 10.3233/RNN-170728] [Reference Citation Analysis]
23 Newland B, Wolff P, Zhou D, Wang W, Zhang H, Rosser A, Wang W, Werner C. Synthesis of ROS scavenging microspheres from a dopamine containing poly(β-amino ester) for applications for neurodegenerative disorders. Biomater Sci 2016;4:400-4. [PMID: 26756041 DOI: 10.1039/c5bm00542f] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
24 Power JH, Barnes OL, Chegini F. Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies. Brain Pathol 2017;27:3-12. [PMID: 26667592 DOI: 10.1111/bpa.12344] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
25 Lamine-Ajili A, Fahmy AM, Létourneau M, Chatenet D, Labonté P, Vaudry D, Fournier A. Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease. Biochim Biophys Acta 2016;1862:688-95. [PMID: 26769362 DOI: 10.1016/j.bbadis.2016.01.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
26 Luna E, Luk KC. Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS Lett 2015;589:3749-59. [PMID: 26505673 DOI: 10.1016/j.febslet.2015.10.023] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
27 Wu Z-, Huang Z, Jiang Q, Dai J, Zhang Y, Gao J, Sun X, Chen N, Yuan Y, Li C, Han Y, Li Y, Ma K. Human and Tree Shrew Alpha-synuclein: Comparative cDNA Sequence and Protein Structure Analysis. Appl Biochem Biotechnol 2015;177:957-66. [DOI: 10.1007/s12010-015-1789-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Vermilyea SC, Emborg ME. α-Synuclein and nonhuman primate models of Parkinson's disease. J Neurosci Methods 2015;255:38-51. [PMID: 26247888 DOI: 10.1016/j.jneumeth.2015.07.025] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
29 Jellinger KA. Neuropathology of Parkinson’s Disease. In: Thomas M, editor. Inflammation in Parkinson's Disease. Cham: Springer International Publishing; 2014. pp. 25-74. [DOI: 10.1007/978-3-319-08046-8_2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
30 Parkkinen L, O'Sullivan SS, Collins C, Petrie A, Holton JL, Revesz T, Lees AJ. Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis 2011;1:277-86. [PMID: 23939308 DOI: 10.3233/JPD-2011-11046] [Cited by in Crossref: 57] [Cited by in F6Publishing: 83] [Article Influence: 6.3] [Reference Citation Analysis]
31 Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ, Rozemuller AJ, van de Berg WD; Netherlands Brain Bank. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Mov Disord 2014;29:1244-51. [PMID: 24996051 DOI: 10.1002/mds.25952] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 10.3] [Reference Citation Analysis]
32 Jang SF, Liu WH, Song WS, Chiang KL, Ma HI, Kao CL, Chen MT. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine. Int J Mol Sci 2014;15:3904-25. [PMID: 24599081 DOI: 10.3390/ijms15033904] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
33 Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. Gene. 2013;532:18-23. [PMID: 23954870 DOI: 10.1016/j.gene.2013.07.085] [Cited by in Crossref: 136] [Cited by in F6Publishing: 118] [Article Influence: 13.6] [Reference Citation Analysis]
34 Ma KL, Gao JH, Huang ZQ, Zhang Y, Kuang DX, Jiang QF, Han YY, Li C, Wang WG, Huang XY, Xu J, Tong PF, Yin XX, Dai JJ. Motor Function in MPTP-Treated Tree Shrews (Tupaia belangeri chinensis). Neurochem Res 2013. [PMID: 23797325 DOI: 10.1007/s11064-013-1099-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
35 Tabrez S, Jabir NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets 2012;11:395-409. [PMID: 22483313 DOI: 10.2174/187152712800792785] [Cited by in Crossref: 86] [Cited by in F6Publishing: 90] [Article Influence: 7.8] [Reference Citation Analysis]
36 Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, Duda JE. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79:2307-14. [PMID: 23152586 DOI: 10.1212/WNL.0b013e318278fe32] [Cited by in Crossref: 94] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
37 Tanikawa S, Mori F, Tanji K, Kakita A, Takahashi H, Wakabayashi K. Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in α-synucleinopathy. Neuroscience Letters 2012;527:16-21. [DOI: 10.1016/j.neulet.2012.08.035] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
38 Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy body in Parkinson's disease and related neurodegenerative disorders. Mol Neurobiol 2013;47:495-508. [PMID: 22622968 DOI: 10.1007/s12035-012-8280-y] [Cited by in Crossref: 211] [Cited by in F6Publishing: 225] [Article Influence: 19.2] [Reference Citation Analysis]
39 Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiology of Disease 2012;45:1051-67. [DOI: 10.1016/j.nbd.2011.12.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
40 Jellinger K. The role of α-synuclein in neurodegeneration — An update. Translational Neuroscience 2012;3. [DOI: 10.2478/s13380-012-0013-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
41 Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012;27:8-30. [PMID: 22081500 DOI: 10.1002/mds.23795] [Cited by in Crossref: 288] [Cited by in F6Publishing: 299] [Article Influence: 24.0] [Reference Citation Analysis]
42 Jellinger KA. Parkinson's Disease. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders 2011. [DOI: 10.1002/9781444341256.ch21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
43 Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 2012;27:709-15. [PMID: 21766334 DOI: 10.1002/mds.23838] [Cited by in Crossref: 287] [Cited by in F6Publishing: 321] [Article Influence: 23.9] [Reference Citation Analysis]
44 Smith BA, Goldberg NR, Meshul CK. Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res 2011;1386:70-80. [PMID: 21315689 DOI: 10.1016/j.brainres.2011.02.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
45 Goldberg NR, Haack AK, Lim NS, Janson OK, Meshul CK. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 2011;180:256-71. [PMID: 21335067 DOI: 10.1016/j.neuroscience.2011.02.027] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
46 Jellinger KA. Neuropathology of Movement Disorders. Youmans Neurological Surgery. Elsevier; 2011. pp. 871-98. [DOI: 10.1016/b978-1-4160-5316-3.00076-9] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Jackson-lewis V, Tocilescu MA, Devries R, Alessi DM, Przedborski S. MPTP and Oxidative Stress: It’s Complicated! Studies on Experimental Models 2011. [DOI: 10.1007/978-1-60761-956-7_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Dugger BN, Dickson DW. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 2010;120:633-9. [PMID: 20721565 DOI: 10.1007/s00401-010-0739-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
49 Goldberg NR, Haack AK, Meshul CK. Enriched environment promotes similar neuronal and behavioral recovery in a young and aged mouse model of Parkinson's disease. Neuroscience 2011;172:443-52. [PMID: 20933577 DOI: 10.1016/j.neuroscience.2010.09.062] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
50 Wakabayashi K, Mori F, Tanji K, Orimo S, Takahashi H. Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 2010;120:1-12. [PMID: 20532896 DOI: 10.1007/s00401-010-0706-x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 114] [Article Influence: 8.3] [Reference Citation Analysis]
51 Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? Brain Res Rev 2010;65:28-55. [PMID: 20685363 DOI: 10.1016/j.brainresrev.2010.05.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
52 Ahn TB. Clinicopathological correlates of lewy body disease: fundamental issues. J Mov Disord 2010;3:11-4. [PMID: 24868372 DOI: 10.14802/jmd.10003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
53 Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson's disease: an anatomical study. Acta Neuropathol 2009;118:777-84. [PMID: 19802627 DOI: 10.1007/s00401-009-0596-y] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
54 Boger HA, Granholm AC, McGinty JF, Middaugh LD. A dual-hit animal model for age-related parkinsonism. Prog Neurobiol 2010;90:217-29. [PMID: 19853012 DOI: 10.1016/j.pneurobio.2009.10.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
55 Hedlund E, Perlmann T. Neuronal cell replacement in Parkinson's disease. J Intern Med 2009;266:358-71. [PMID: 19765180 DOI: 10.1111/j.1365-2796.2009.02155.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
56 Jellinger KA. A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2009;1792:730-40. [DOI: 10.1016/j.bbadis.2008.07.006] [Cited by in Crossref: 167] [Cited by in F6Publishing: 178] [Article Influence: 11.9] [Reference Citation Analysis]
57 Nakamura K, Nemani VM, Wallender EK, Kaehlcke K, Ott M, Edwards RH. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. J Neurosci 2008;28:12305-17. [PMID: 19020024 DOI: 10.1523/JNEUROSCI.3088-08.2008] [Cited by in Crossref: 149] [Cited by in F6Publishing: 160] [Article Influence: 10.6] [Reference Citation Analysis]
58 Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit. Mov Disord 2008;23:1608-12. [PMID: 18649394 DOI: 10.1002/mds.22207] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
59 Dinh K, Poindexter BJ, Barnes JL, Schiess MC, Bick RJ. Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Cytokine 2009;45:179-83. [PMID: 19157893 DOI: 10.1016/j.cyto.2008.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
60 Hong S, Lee HK, Kim CY, Seong GJ. Identification and localization of alpha-synuclein in human cornea. Korean J Ophthalmol 2008;22:145-6. [PMID: 18612236 DOI: 10.3341/kjo.2008.22.2.145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
61 Maguire-Zeiss KA. alpha-Synuclein: a therapeutic target for Parkinson's disease? Pharmacol Res 2008;58:271-80. [PMID: 18840530 DOI: 10.1016/j.phrs.2008.09.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
62 Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1-16. [PMID: 18592254 DOI: 10.1007/s00401-008-0406-y] [Cited by in Crossref: 148] [Cited by in F6Publishing: 176] [Article Influence: 9.9] [Reference Citation Analysis]
63 Fujishiro H, Frigerio R, Burnett M, Klos KJ, Josephs KA, Delledonne A, Parisi JE, Ahlskog JE, Dickson DW. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 2008;23:1085-92. [DOI: 10.1002/mds.21989] [Cited by in Crossref: 130] [Cited by in F6Publishing: 130] [Article Influence: 8.7] [Reference Citation Analysis]
64 Fato R, Bergamini C, Leoni S, Strocchi P, Lenaz G. Generation of Reactive Oxygen Species by Mitochondrial Complex I: Implications in Neurodegeneration. Neurochem Res 2008;33:2487-501. [DOI: 10.1007/s11064-008-9747-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 4.1] [Reference Citation Analysis]
65 Wakabayashi K, Tanji K, Mori F, Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 2007;27:494-506. [PMID: 18018486 DOI: 10.1111/j.1440-1789.2007.00803.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 252] [Article Influence: 20.3] [Reference Citation Analysis]
66 Halliday GM, Mccann H. Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms. Experimental Neurology 2008;209:12-21. [DOI: 10.1016/j.expneurol.2007.07.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
67 Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasić JR, McGlothan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008;105:78-90. [PMID: 17988241 DOI: 10.1111/j.1471-4159.2007.05108.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 5.4] [Reference Citation Analysis]
68 Ortega R, Cloetens P, Devès G, Carmona A, Bohic S. Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS One 2007;2:e925. [PMID: 17895967 DOI: 10.1371/journal.pone.0000925] [Cited by in Crossref: 116] [Cited by in F6Publishing: 136] [Article Influence: 7.3] [Reference Citation Analysis]